We would love to hear your thoughts about our site and services, please take our survey here.
Dr. Coughlin, Sept 2023.
Her words, not mine and not any FUD spreader.
I am delighted to have the opportunity to work with them to complete the hugely successful dose escalation study and move into the dose expansion study in soft tissue sarcoma patients later this year.
"Beyond that we have potential to exploit AVA6000 to treat other cancers such as breast and ovarian and a wealth of opportunities to build our pipeline and partnerships. I am looking forward to working with the team on this strategy at this very exciting time."
As we head into a pivotal week, it is worth digesting the below again, word for word.
"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.
"Not only are the initial safety data emerging from the AVA6000 Phase 1 study, across all dose cohorts, remarkably good, but targeted release of doxorubicin in the tumour has been confirmed both by analysis of tumour biopsies and now by clear clinical responses.
"Even at this early stage and in this patient group, we have a confirmed, significant reduction in tumour volume in a patient with soft tissue sarcoma, as well as other positive signals across a number of patients.
In light of the highly positive Phase 1a data, the Company has adapted its clinical development strategy with the aim of bringing forward the start of a potentially pivotal Phase 2 study, subject to receiving the necessary regulatory approvals.
Hello
· Following completion of the Anchois well, Energean will have the right to acquire a further 10% of Chariot's equity in the Lixus licence for:
o US$850 million gross development carry to first gas (including the US$85m gross carry)
o US$50 million 5-year zero coupon convertible loan note with a strike price of £20 adjusted down for dividends or issuance of three million Energean shares, at Chariot's option on FID
o 7% royalty payment on Energean's gas production revenues in excess of a base hurdle on the realised gas price (post transportation costs)